Briefing
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia (FLAIR, extended follow-up)
Extended follow-up (median 62.2 months) and increased enrollment. Undetectable BM MRD within 2 years: 172/260 (66.2%) with I+V vs 0/263 with ibrutinib alone (P<0.001) vs 127/263 (48.3%) with FCR. Progression or death: 18 (6.9%) I+V vs 59 (22.4%) ibrutinib (HR 0.29, 95% CI 0.17-0.49, P<0.001) vs 112 (42.6%) FCR (HR 0.13, 95% CI 0.08-0.21, P<0.001). 5-year PFS 93.9% vs 79.0% vs 58.1%. OS also favored I+V (HR 0.41 vs ibrutinib; HR 0.26 vs FCR). Level 1.
- Design: paper
- n: 260 I+V, 263 ibrutinib, 263 FCR
- Assay: Undetectable BM MRD within 2 years; MRD-guided I+V vs ibrutinib vs FCR